Funding news
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. Closes

Recently funded · $60.0M Series bHospitals and Health CareUSView source

Get the full Tarsus Pharmaceuticals, Inc. company profile

Access contacts, investors, buying signals & more

Open in Dashboard

Tarsus Pharmaceuticals, Inc., the biopharmaceutical company known for applying proven science and new technology to revolutionize patient treatment, has closed a $60.0M Series B funding round.

The capital infusion will bolster the NASDAQ-listed firm (TARS) as it continues to advance its pipeline, with an initial and significant focus on eye care. Tarsus aims to identify and address unmet needs in patient care by leveraging established scientific principles to develop innovative and effective therapeutic solutions.

Other United States companies recently funded

View all

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#CompanyAmount
1
Shockwave Medical logo

Shockwave Medical

United States

$13.1B
2
NeuroEM Therapeutics logo

NeuroEM Therapeutics

United States

$7.2B
3
GRAIL logo

GRAIL

United States

$7.1B
4
Illumina logo

Illumina

United States

$7.1B
5
RemeGen Biosciences logo

RemeGen Biosciences

United States

$5.6B

Other recent Series b rounds

Companies that recently closed a Series b round.

#CompanyAmount
1
Catch Co. logo

Catch Co.

United States

$38.0M
2
Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc.

United States

$21.0M
3
BlackSwan Technologies logo

BlackSwan Technologies

United Kingdom

$79.3M
4
Unity logo

Unity

United States

$12.0M
5
Insolight logo

Insolight

Switzerland

$5.0M